These innovative molecules represent a significant advancement in the therapy of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates remarkable efficacy in controlling blood glucose https://albertycnw720027.ezblogz.com/70702044/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide